Neurocrine Biosciences Inc on Monday launched its add-on treatment for patients with Parkinson's disease nearly five months after Food and Drug Administration's approval, as the COVID-19 pandemic ...

The submission is based on results from the TEMPO clinical development program that evaluated the efficacy, safety and tolerability of tavapadon across a broad Parkinson's disease ...

AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from ...